中国药物经济学2026，Vol.21Issue(2)：10-14,5.DOI:10.12010/j.issn.1673-5846.2026.02.002
转移性前列腺癌患者延长中位无进展生存时间的长期卫生成本和健康获益评价
Long-Term Value Analysis of Improvements in Median Progression-Free Survival in Metastatic Prostate Cancer
颜毅 1陶立波 2刘畅 1吴瑶 1王芳旭 1孙爽1
作者信息
- 1. 北京大学医学部卫生政策与技术评估中心,北京 100191
- 2. 北京大学医学部卫生政策与技术评估中心,北京 100191||北京大学公共卫生学院卫生政策与管理学系,北京 100191
- 折叠
摘要
Abstract
Objective To demonstrate the long-term value of median progression-free survival(mPFS)improvement by calculating the relationship between mPFS and long-term healthcare costs and health outcomes in the treatment of metastatic prostate cancer(mPC).Methods A Markov model was developed based on the disease progression of mPC.The mathematical relationship between mPFS improvement and long-term costs and health outcomes were quantified and analyzed under the standard treatment scenario.Sensitivity analyses were conducted on key parameters.Results For mPC patients,with one incremental month of mPFS,quality-adjusted life years(QALYs)will increase by an average of 0.06.Incremental healthcare costs dynamic,ranging from 1780.70 yuan to-764.1 yuan,with an average of 271.99 yuan.The calculated long-term value for each incremental month of mPFS is 5472.95 yuan.Sensitivity analyses revealed robust health outcome results,while healthcare cost were significantly influenced by costs in the progressive disease(PD)and progression-free survival(PFS)states.Conclusion Establishing an appropriate quantitative methodology to assess the long-term value of mPFS improvement in mPC treatment so as to support relevant healthcare decision-making rapidly.关键词
转移性前列腺癌/中位无进展生存期/长期价值/健康获益/卫生成本Key words
Metastatic prostate cancer/Median progression-free survival/Long-term value/Clinical benefit/Medical costs分类
医药卫生引用本文复制引用
颜毅,陶立波,刘畅,吴瑶,王芳旭,孙爽..转移性前列腺癌患者延长中位无进展生存时间的长期卫生成本和健康获益评价[J].中国药物经济学,2026,21(2):10-14,5.
